CRL-40,940

Add links
Source: Wikipedia, the free encyclopedia.
CRL-40,940
Identifiers
  • (2-Amino-2-oxoethyl)[bis(4-fluorophenyl)methyl]sulfoniumolate
JSmol)
  • C1=CC(=CC=C1C(C2=CC=C(C=C2)F)S(=O)CC(=O)N)F
  • InChI=1S/C15H13F2NO2S/c16-12-5-1-10(2-6-12)15(21(20)9-14(18)19)11-3-7-13(17)8-4-11/h1-8,15H,9H2,(H2,18,19)
  • Key:YEAQNUMCWMRYMU-UHFFFAOYSA-N

CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is the bisfluoro analog of modafinil.[1][2][3][4][5] It is a eugeroic as well as a weak dopamine reuptake inhibitor. Its inventors claim that it is more effective than modafinil and adrafinil, with fewer side effects. It was patented in 2013, and pre-clinical trials have been underway since December 2015.[6]

See also

References

  1. ^ CA 1199916, Lafon L, "Benzhydrylsulfinylacetamide derivatives", published 28 January 1986 
  2. PMID 21344069
    .
  3. ^ US 20130295196, Konofal E, "Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof", published 7 November 2013 
  4. ^ "Flmodafinil Dosage: How Much Should You Take and When?". modaforum.org. Retrieved 2023-09-26.
  5. ^ Louis Lafon (18 December 1984). "Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids". Retrieved 25 July 2015.
  6. ^ "Pipeline". NLS Pharmaceuticals.
Retrieved from "https://en.wikipedia.org/w/index.php?title=CRL-40,940&oldid=1216731335"